Straight explanations of the peptides we prescribe, the labs behind them, and the regulations that shape what's actually legal — written by the same team that reviews your panel.
A straight answer on BPC-157 — why we require labs first, and why the FDA's July 23–24 hearing on its compounding status matters for anyone considering it.
Read the PostFDA Pharmacy Compounding Advisory Committee reviews BPC-157 for the 503A Bulks List on July 23, 2026.
Why we require labs before prescribing it, and what the FDA's July 23–24 hearing could mean for its legal compounding status.
Read MoreThe shortage is over — here's what that actually changed, what's still legal under 503A, and what the April 2026 FDA proposal means for you.
Read MoreIt's not a formality — it's the baseline every future retest gets measured against. Here's why we never waive it.
Read MoreBoth share the same recovery foundation. Here's the plain-language breakdown of what sets them apart — and how to pick.
Read MoreWe're adding to this library regularly — check back, or follow @FLAPeptides for updates when a new post goes live.
